30 March 2023
EMA/CHMP/113220/2023
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion[1] (initial authorisation)

Epysqli

eculizumab

On 30 March 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Epysqli, intended for the treatment of adults and children with paroxysmal nocturnal haemoglobinuria (PNH). The applicant for this medicinal product is Samsung Bioepis NL B.V.

Epysqli will be available as a 300 mg concentrate for solution for infusion. The active substance of Epysqli is eculizumab, a selective immunosuppressant (ATC code: L04AA25). Eculizumab is a recombinant humanised monoclonal IgG2/4k antibody that binds to the human C5 complement protein and thereby inhibits the activation of terminal complement.

Epysqli is a biosimilar medicinal product. It is highly similar to the reference product Soliris (eculizumab), which was authorised in the EU on 20 June 2007. Data show that Epysqli has comparable quality, safety and efficacy to Soliris (eculizumab). More information on biosimilar medicines can be found here.

The full indication is:

> Epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1).

Epysqli must be administered by a healthcare professional and under the supervision of a physician experienced in the management of patients with haematological disorders.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

[1] Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union